NIP
ZNTL icon

Nicholas Investment Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Nicholas Investment Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-158,704
Closed -$3.44M – 201
2022
Q3 		$3.44M Buy
+158,704
New +$4.34M 0.32% 94

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nicholas Investment Partners's ZNTL Position: Q4 2022 in Review

Nicholas Investment Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2022, closing a stake of 158,704 shares — an estimated $3.44M sold.

Nicholas Investment Partners first reported a position in ZNTL in Q3 2022 and held it in 1 quarter. The position peaked at $3.44M in Q3 2022. 106 funds tracked by Wall St. Rank hold ZNTL as of Q4 2022.

  • Nicholas Investment Partners reported no remaining Zentalis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 158,704 Zentalis Pharmaceuticals shares in Q4 2022, an estimated $3.44M.
  • Nicholas Investment Partners first reported a position in Zentalis Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Nicholas Investment Partners's Zentalis Pharmaceuticals position peaked at $3.44M in Q3 2022.
  • 106 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2022.

Based on Nicholas Investment Partners's 13F filing for Q4 2022, filed 10 Feb 2023.